Promosi Sosial Media

Prostate cancer breakthrough: Experts stunned by success of ‘Trojan Horse’ therapy
By Andrew Gregory, Daily Mirror

Prostate cancer patients  have been given new hope after scientists eliminated the disease in mice.

Experts are stunned by the success of the “Trojan Horse” therapy, which involves hiding cancer-killing viruses inside the immune system to sneak them into a tumour.

Tens of thousands of the friendly viruses are inserted deep in tumours before being released all at once to kill cancerous cells.

Those on other treatments died after the cancer spread.

After chemo or radiotherapy, the tissue is damaged, causing a surge in white blood cells, which swamp the area to help repair the damage.

Under the pioneering treatment, it is these white cells that are used to carry the cancer-killing viruses.

"We’re surfing that wave to get as many white blood cells to deliver tumour-busting viruses into the heart of a tumour.”

Mice were injected with the “spiked” white cells two days after chemo ended.

‘Trojan horses’ deliver blows to tumors
by Amy Pullan-Sheffield

Researchers from the University of Sheffield have discovered white blood cells, called macrophages, surge into tumors after frontline therapies, like chemotherapy or radiotherapy, and are now exploiting this to deliver a second potent blow to stop tumors from growing back.

Each macrophage then releases large amounts of virus inside the tumor.

The virus then kills the cancer residue from within, preventing regrowth or further spread of the cancer to other parts of the body.

“Our Trojan-horse can convert a patient’s own white blood cells into tiny tumor-killing machines which fight to prevent tumor regrowth after the end of chemo or radio therapy treatment,” says Claire Lewis, a professor in the oncology department at Sheffield, who co-led the project.

The research, reported in the journal Cancer Research, shows that the therapy completely eradicates primary and metastic prostate tumors after chemo or radiotherapy. Researchers hope clinical trials in prostate cancer patients could begin as early as next year.